Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Peptimmune Inc.

www.peptimmune.com

Latest From Peptimmune Inc.

Merck Serono ditches another multiple sclerosis candidate

Merck Serono's future prospects in the multiple sclerosis market look even less impressive following its decision to drop a Phase II multiple sclerosis candidate that it licensed from Japanese firm Ono Pharmaceutical in 2011 for around €14m up front. The German company said ONO-4641/ceralifimod did not meet its threshold for continued investment, and that the termination decision was a mutual agreement.

Neurology Immune Disorders

Merck Serono DreaMS of securing MS franchise with Ono deal

Merck Serono has signed two collaboration agreements with Japan's Ono Pharmaceutical with a view to strengthening two of its franchises, those covering multiple sclerosis (MS) and cancer.

Cancer Neurology

Deals Shaping the Medical Industry (10/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Merck Serono buys Phase I Copaxone relative in bankruptcy sale

Merck Serono has paid $1.5 million for PI-2301, a peptide copolymer that its now bankrupt former owner Peptimmune described as a "next-generation Copaxone". The asset had previously been optioned to Novartis.

Neurology Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Peptimmune Inc.
  • Senior Management
  • Eric Zanelli, PhD, VP, Research
  • Contact Info
  • Peptimmune Inc.
    Phone: (617) 715-8000
    64 Sidney St., Ste. 380
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register